Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Neoadjuvant Therapy of Pembrolizumab Combined With Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer: An Open-label Single-arm Phase II Study

NCT04040361 is registered in ClinicalTrials.gov with Masahiro Tsuboi as lead sponsor.

NCT NCT04040361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04040361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Neoadjuvant Therapy of Pembrolizumab Combined With Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer: An Open-label Single-arm Phase II Study
Lead sponsor
Masahiro Tsuboi
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2019
Completion date
November 30, 2025
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer stage ib, non-small cell lung cancer stage ii, non-small cell lung cancer stage Ⅲa